about
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of LiteratureSipuleucel-T (Provenge®) for castration-resistant prostate cancerCan high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.Locally advanced paranasal sinus carcinoma: A study of 30 patientsA comprehensive outlook on intracerebral therapy of malignant gliomas.Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.Immunotherapy for the treatment of prostate cancer.Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/mlAdjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen.Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience.Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell-Renal Cell Carcinoma.Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.A Challenging Surgical Approach to Locally Advanced Primary Urethral Carcinoma: A Case Report and Literature Review.Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study.Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.The therapy of kidney cancer with biomolecular drugs.Toxicities of targeted therapy and their management in kidney cancer.Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.New perspectives in the therapy of castration resistant prostate cancer.Peg-filgrastim and cabazitaxel in prostate cancer patients.Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report.Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review.Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.Biomarkers in localized prostate cancer.Serum and tissue markers in colorectal cancer: State of art.The emerging role of obesity, diet and lipid metabolism in prostate cancer.Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Combination therapy for metastatic renal cell carcinoma.Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma.Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers.Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.
P50
Q26750735-3939B769-D51A-46C7-AEEB-7A8D8A45C71BQ26991753-6E66A365-F8EE-4F97-9909-043AD9E60B35Q33390204-25EBD495-529F-44D3-BCE8-88F7813C8CF8Q33390463-83FCB9CC-F8A7-4197-B947-532E2FACFC98Q33566981-5AEBD66D-A0B6-4D37-9CA4-9927D0C74F4DQ33598253-A7912F41-CAA4-46C2-8FB0-D486B8107095Q33708333-26CA7FCE-0516-478E-99A5-CF4ED1435777Q34015600-52E87FE1-2E68-4EED-B46E-8D6EBF1B6916Q34186928-447F448A-8847-499E-B43E-655754D80C3EQ34825819-6716AD15-E4C5-49BF-86B3-EED327AFE371Q35743480-36F7F908-F887-4CEE-B5F9-EB052776DC34Q36207083-AC912499-D75E-431C-8851-EED8C57563B2Q36299355-604C3E0E-C78F-46F0-AC4C-1B05DB8D9FC3Q36421012-3E028C81-831A-4B9C-ACAE-318BE5EBFDE0Q36993531-F8A1AABF-086B-450A-BCDC-888F898B2812Q37516498-0C262229-A06B-4B95-A9CF-EB88D1B44981Q37795307-1613C2CB-F992-439E-BB1B-88D33EDF5741Q37815605-2854438E-6769-44FE-9E3F-88ACE7F11FB6Q37833262-D856677F-B5EE-4382-AB2C-F4397FBBFE96Q38000450-892F1239-A059-4ADB-8418-9C240A6A7AECQ38050162-3DBEB8E2-B3B3-44D2-824E-DF3820BD276DQ38050328-55DED6F6-DE4C-4C2D-B3D9-CA919034F25BQ38282448-8A37D7A2-8761-43CF-96C6-555084430C62Q38345817-B11431D3-D1AA-41F7-8CAA-A90A13E3BD6CQ38588658-4CF091F4-068F-4C13-8F5D-75253C7F45A8Q38621201-ED903CD0-E256-40BB-A803-8F686EAA746AQ38696205-1AA9A72E-F1CB-40EA-8282-E8748C3C7662Q38697114-91E6E2D4-3946-4ECE-9B03-1CD219A0DC3DQ38750780-7B19A248-494C-476A-A771-9F2167BEFBC2Q38821546-670EB5F0-7E3E-4A59-BDD6-80D354046208Q38866506-8D8D0792-2B9D-4289-B0F6-C1344572B401Q38910154-D004630E-001A-49BF-9F34-7D9AA98649C9Q38994030-B8C44F1B-3357-4F96-AA42-559494EDACD4Q39155556-8703DE17-9EBF-4BFA-8AAE-44121BB9B501Q39411127-82824D16-B2D1-4501-AB38-06BD0C7BAB0BQ39448298-3B9C3AC3-73C3-42A1-BAB2-946EC66B6193Q39709661-D0ED6933-AE80-4AFD-A5A4-0058D748FDEEQ40033029-07D3D91F-C9AA-4DDA-AFD3-64E02EA0D033Q40294732-957A85E8-5165-4D6C-A150-1A03BB25BFB3Q40458086-BC9FF2EC-4A1C-4405-96A3-C8F3B85158C9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carlo Buonerba
@ast
Carlo Buonerba
@en
Carlo Buonerba
@es
Carlo Buonerba
@nl
Carlo Buonerba
@sl
type
label
Carlo Buonerba
@ast
Carlo Buonerba
@en
Carlo Buonerba
@es
Carlo Buonerba
@nl
Carlo Buonerba
@sl
prefLabel
Carlo Buonerba
@ast
Carlo Buonerba
@en
Carlo Buonerba
@es
Carlo Buonerba
@nl
Carlo Buonerba
@sl
P106
P1153
35589383200
P21
P31
P496
0000-0002-1806-442X